rpl-6 Antibody

What is RPL6 and why is it important in scientific research?

RPL6 (ribosomal protein L6) is a component of the 60S ribosomal subunit, also known by synonyms including TXREB1, TAXREB107, SHUJUN-2, and Neoplasm-related protein C140. Beyond its canonical role in ribosome biogenesis, RPL6 has emerged as a multifunctional protein involved in several critical cellular processes. Recent studies have demonstrated that RPL6 directly interacts with histone H2A and participates in the DNA damage response (DDR) . Additionally, RPL6 has been implicated in cancer progression, as it is upregulated in multidrug-resistant cancer cells and can protect gastric cancer cells from drug-mediated apoptosis . RPL6 also promotes proliferation and tumorigenesis of gallbladder cancer cells through interaction with NSUN2 . These non-canonical functions make RPL6 an important research target for understanding both fundamental cellular processes and disease mechanisms.

What types of RPL6 antibodies are currently available for research?

Several types of RPL6 antibodies are available for research applications, including:

• Monoclonal antibodies: Mouse anti-RPL6 monoclonal antibody (clone AB01/1E12), which offers high specificity for targeted epitopes of human RPL6 .

• Polyclonal antibodies: Rabbit anti-RPL6 polyclonal antibodies that demonstrate reactivity with human, mouse, and rat samples .

The choice between monoclonal and polyclonal antibodies depends on your experimental requirements. Monoclonal antibodies typically offer higher specificity for a single epitope, while polyclonal antibodies recognize multiple epitopes and may provide stronger signals in certain applications.

What is the expected molecular weight of RPL6 in Western blot analysis?

When performing Western blot analysis, RPL6 typically appears as a band at approximately 33-34 kDa . Specifically, mouse anti-RPL6 antibody detects a band of approximately 33 kDa in Jurkat cell lysates , while other antibodies report an observed molecular weight of 34 kDa . Minor variations in the detected molecular weight may occur depending on the cell line or tissue sample used, post-translational modifications, or the specific antibody employed.

What applications are RPL6 antibodies suitable for in research settings?

RPL6 antibodies have been validated for multiple experimental applications:

How should RPL6 antibodies be stored and handled to maintain optimal performance?

Proper storage and handling of RPL6 antibodies is crucial for maintaining their activity and specificity:

Always follow the manufacturer's specific recommendations, as storage conditions may vary between antibody formulations.

How does RPL6 participate in the DNA damage response (DDR)?

Recent research has uncovered a non-canonical role for RPL6 in the DNA damage response pathway:

• Recruitment to damage sites: RPL6 is recruited to DNA damage sites in a poly(ADP-ribose) polymerase (PARP)-dependent manner . This recruitment can be suppressed by the PARP inhibitor olaparib, indicating that PARP activity is required for RPL6 localization to damage sites .

• Interaction with histone H2A: At damage sites, RPL6 directly interacts with histone H2A, as demonstrated by immunoprecipitation and mass spectrometry analysis . This interaction is critical for subsequent steps in the DDR cascade.

• Facilitation of repair protein recruitment: RPL6 promotes the recruitment of DNA repair proteins to damage sites. Depletion of RPL6 impairs the formation of MDC1 foci after IR exposure and abrogates the accumulation of 53BP1 and BRCA1 at DNA damage sites . Notably, RPL6 knockdown does not affect γH2AX level or foci formation but interferes with the recruitment of MDC1 to damage sites by γH2AX .

• Impact on DNA repair pathways: RPL6 depletion decreases the efficiency of both non-homologous end joining (NHEJ) and homologous recombination (HR) repair pathways . This suggests a fundamental role for RPL6 in maintaining genome integrity through multiple repair mechanisms.

What experimental approaches can be used to study RPL6's role in DNA damage repair?

Several experimental approaches have been successfully employed to investigate RPL6's role in DNA repair:

• siRNA-mediated knockdown: Transfection with RPL6-specific siRNAs to deplete the protein and assess effects on DNA damage response and repair .

• Immunofluorescence microscopy: To visualize the recruitment of RPL6 and other repair proteins to DNA damage sites, either after ionizing radiation (IR) exposure or laser microirradiation .

• Co-immunoprecipitation (Co-IP): To detect interactions between RPL6 and other proteins involved in the DNA damage response, such as histone H2A and MDC1 .

• Reporter assays: To quantify the efficiency of NHEJ and HR repair pathways in cells with normal or depleted levels of RPL6 .

• Cell cycle analysis: To examine the effect of RPL6 depletion on the G2-M checkpoint by staining with phosphohistone H3 and propidium iodide, followed by FACS analysis .

• His-ubiquitin pulldown: To investigate the role of RPL6 in protein ubiquitination events during the DNA damage response .

These methodologies can be combined to provide a comprehensive understanding of RPL6's function in maintaining genome integrity.

What is the relationship between RPL6 and cancer progression?

RPL6 has been implicated in multiple aspects of cancer biology:

• Drug resistance: RPL6 is upregulated in multidrug-resistant cancer cells, suggesting a role in the development of treatment resistance .

• Apoptosis protection: RPL6 can protect gastric cancer cells from drug-mediated apoptosis, potentially contributing to therapeutic failures .

• Cell growth and cycle progression: Down-regulation of RPL6 in gastric cancer treatments has been shown to suppress cell growth and cell cycle progression, indicating its pro-tumorigenic role .

• Tumorigenesis: RPL6 promotes proliferation and tumorigenesis of gallbladder cancer cells through interaction with NSUN2 .

• DNA repair defects: Since RPL6 plays a role in DNA damage repair, its dysregulation may contribute to genomic instability, a hallmark of cancer .

Understanding these connections may lead to novel therapeutic approaches targeting RPL6 in cancer treatment strategies.

How can I validate the specificity of my RPL6 antibody?

Validating antibody specificity is crucial for reliable experimental results. For RPL6 antibodies, consider these approaches:

• Positive and negative controls: Use cell lines known to express RPL6 (such as HEK-293T, HeLa, HepG2, or Jurkat cells) as positive controls . For negative controls, consider using RPL6-knockdown cells generated by siRNA or CRISPR-Cas9.

• Western blot analysis: Verify that the antibody detects a single band at the expected molecular weight (33-34 kDa) . Multiple bands or bands at unexpected molecular weights may indicate non-specific binding.

• siRNA knockdown validation: Compare the signal intensity between control cells and cells treated with RPL6-specific siRNAs. A significant reduction in signal in knockdown cells confirms antibody specificity.

• Immunoprecipitation followed by mass spectrometry: This can confirm that the antibody is pulling down RPL6 rather than cross-reacting with other proteins.

• Cross-reactivity testing: If working across species, validate the antibody's performance in each species of interest, as reactivity may vary.

What are common challenges when using RPL6 antibodies for immunoprecipitation studies?

When using RPL6 antibodies for immunoprecipitation to study protein-protein interactions, researchers may encounter several challenges:

• Cross-linking conditions: When studying interactions between RPL6 and chromatin components like histone H2A, appropriate cross-linking conditions are crucial. Insufficient cross-linking may fail to capture transient interactions, while excessive cross-linking can create artificial associations.

• Nuclear extraction efficiency: Since RPL6 functions both in the cytoplasm (for ribosome assembly) and nucleus (for DNA damage response), efficient nuclear extraction protocols are essential to study its nuclear interactions.

• Background binding: High background can mask specific interactions. Using proper blocking agents and stringent washing conditions can help reduce non-specific binding.

• Antibody orientation: Consider using tagged RPL6 constructs (such as FLAG-RPL6) for immunoprecipitation with tag-specific antibodies, which can sometimes yield cleaner results than direct immunoprecipitation with RPL6 antibodies .

• Validation of interactions: Confirm RPL6 interactions through reciprocal immunoprecipitations and alternative techniques such as proximity ligation assays or FRET to validate direct protein-protein interactions.

How can I study the dynamic recruitment of RPL6 to DNA damage sites?

Investigating the dynamic recruitment of RPL6 to DNA damage sites requires specialized techniques:

• Laser microirradiation: This technique allows for the induction of localized DNA damage and real-time tracking of protein recruitment. Cells expressing fluorescently tagged RPL6 can be monitored by live-cell imaging after laser microirradiation to observe the kinetics of RPL6 recruitment .

• PARP inhibition studies: Since RPL6 recruitment is PARP-dependent, combining laser microirradiation with PARP inhibitors like olaparib can provide insights into the mechanism of recruitment .

• Fluorescence recovery after photobleaching (FRAP): This technique can measure the mobility and residence time of RPL6 at damage sites, providing information about the stability of its association with damaged chromatin.

• Super-resolution microscopy: Techniques such as STORM or PALM can provide nanoscale resolution of RPL6 localization relative to other DNA damage response proteins, revealing spatial organization at damage sites.

• ChIP-seq after damage induction: This approach can map RPL6 binding sites across the genome following DNA damage, potentially identifying preferential recruitment to specific genomic regions.

What experimental models are most appropriate for studying RPL6's role in cancer biology?

Several experimental models can be employed to investigate RPL6's functions in cancer:

• Cancer cell lines with varying RPL6 expression: Comparing cell lines with different endogenous levels of RPL6 can reveal correlations between RPL6 expression and cancer phenotypes.

• Genetic manipulation models:

  • RPL6 knockdown using siRNA or shRNA in cancer cell lines

  • RPL6 overexpression systems to mimic upregulation observed in drug-resistant cancers

  • CRISPR-Cas9 gene editing to create RPL6-knockout or mutant cell lines

• Patient-derived xenografts (PDX): These models maintain the characteristics of original patient tumors and can be used to assess the correlation between RPL6 expression and drug resistance or tumor progression.

• 3D organoid cultures: These better recapitulate tumor microenvironments than 2D cultures and can be used to study RPL6's impact on tumor growth and response to therapies.

• Animal models: Conditional knockout or transgenic mouse models with altered RPL6 expression can provide insights into its role in tumor initiation, progression, and therapy response in vivo.